Descripción de un caso de leucemia mieloide crónica con un cromosoma Philadelphia variante
Barra lateral del artículo
Contenido principal del artículo
Resumen
En 5–10% de los casos de Leucemia Mieloide Crónica (LMC), el cromosoma Philadelphia (Ph1) se origina como producto de translocaciones variantes (Ph1 variante). Estas últimas involucran otros autosomas además del 9 y 22 clásicamente implicados. Se presenta aquí un caso de LMC cuyo cromosoma Ph1 variante fue originado a partir de una translocación compleja que involucró los cromosomas 3, 9 y 22 [t(3;9;22)(p21,q34;q11)]. El análisis mediante FISH sugiere un mecanismo de formación en una etapa única, mientras el análisis por RT-PCR mostró la presencia del rearreglo molecular BCR/ABL1 correspondiente a la isoforma p210. El paciente no presentó variaciones significativas en los parámetros de respuesta clínica (respuesta hematológica, respuesta citogenética y respuesta molecular) respecto de aquellos pacientes con el Ph1 estándar.
Descargas
Detalles del artículo
La Revista de Ciencia y Tecnología sostiene su compromiso con las políticas de Acceso Abierto a la información científica, al considerar que tanto las publicaciones científicas como las investigaciones financiadas con fondos públicos deben circular en Internet en forma libre y gratuita. Los trabajos publicados en la Revista de Ciencia y Tecnología están bajo la licencia Creative Commons Atribución-NoComercial 2.5 Argentina.
Citas
Kantarjian H, Talpaz M, Giles F, [et al]. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Annals of Internal Medicine 19; 145: 913–923. 2006.
Kurzrock R, Kantarjian HM, Druker BJ, [et al]. Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics. Annals International Medicine 10, 138: 819–830. 2003.
Nowell PC & Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science, 132: 1497. 1960.
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia. Nature 243: 290–293. 1973.
Rowley JD. The critical role of chromosome translocations in human leukemias. Annual Review of Genetics 32: 495–519. 1998.
Fröling S & Dohner H. Chromosomal abnormalities in cancer. The New England Journal of Medicine 359: 722-34. 2008.
Goldman J. & Melo J. Chronic myeloid leukemia-advances in biology and new approaches to treatment. The New England Journal of Medicine 349: 1451–1464. 2003.
Melo JV, Hughes TP & Apperley JF. Chronic myeloid leukemia Hematology/American Society of Hematology 1: 132–137. 2003.
Heim S & Mitelman F. Cancer cytogenetics, 3rd Edition. Hoboken, New Jersey, Wiley Blackwell, a John Wiley & Sons, Inc., publication. Cap 7, p179–207. 2009
Gallego S, Baialardo E, Gutiérrrez M, [et al]. A new variant Ph translocation in chronic myeloid leukemia: t(Y;22)(p11;q11). Cancer Genetics and Cytogenetics 87: 75–78.1996
Naumann S & Decker H. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 147: 18–22. 2003.
Fisher AM, Strike P, Scott C, [et al]. Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-richest regions of the genome. Genes Chromosomes & Cancer 43: 383–389. 2005.
Bennour A, Sennana H, Laatiri A, [et al]. Molecular cytogentic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genetics and Cytogenetics 194: 30–37. 2009.
Richerbourg S, Eclache V, Perot C, [et al]. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genetics and Cytogenetics 182: 95–102. 2008.
Gorusu M, Benn P, Li Z [et al]. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 173: 97–106. 2007.
Belli C, Alú MF, Alfonso G, [et al]. Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. Cytogenetic and Genome Research 132, 4: 304–308. 2011.
Reid AG, Huntly BJ, Grace C, [et al]. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology 121: 419–427. 2003.
Yehuda O, Abeliovich D, Ben-Neriah S, [et al]. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph negative and variant Ph-positive. Cancer Genetics and Cytogenetics, 114:100–107. 1999.
Reddy KS & Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genetics and Cytogenetics, 118:121–131. 2000.
Loncarevic IF, Romer J, Starke H, [et al]. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes & Cancer 34: 193–200. 2002.
Shaffer L, Slovak M & Campbell L editors. International Standing Committee on Human Cytogenetic Nomenclature. An International System for Human Cytogenetic Nomenclature. Cytogenetic and Genome Research. 2009.
Cross N. Detection of BCR-ABL in Hematological Malignancies by RT-PCR. Cotter F.E. Molecular Diagnosis of Cancer. Cap 2, p 25–36. 1996.
Mitelman Database of Chromosome Aberrations in Cancer. (2013). Mitelman F, Johansson B & Mertens F. Available at http://cgap.nci.nih.gov/Chromosomes/Mitelman. (verificado: Sep 2015).
Barbata G, Granata G, Bellanca F, [et al]. Complex trasnlocation t(3;9;22) and paracentric inversion of chromosome 3 in blastic crisis of chronic myeloid leukemia. Cancer Genetic and Cytogenetic 20: 305–309. 1986.
Albano F, Anelli L, Zagaria A, [et al]. Non-random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Molecular Cancer, 9:120. 2010.
Bennour A, Bellâaj H, Youssef B, [et al], Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. Journal of Cancer Research and Clinical Oncology 137:1329–1336. 2011.
Buda G, Orciulo E, Maggini V, [et al]. Complex translocation t(3;9;22)(p21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leukemia research, 32: 192–194. 2008.
Tan J, Cang S, Seiter K, [et al]. t(3;9;22) 3-Way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Investigation, 27:718–722. 2009.
Gutiérrez LG, Belli C, Ferri C, [et al]. Clonal Evolution and Cytogenetic Changes in Chronic Myeloid Leukemia. Urbano K., NOVA Publisher group: Advances in genetics Research. Vol. 11, Cap 8, p 181–200. 2014. Available at https://www.novapublishers.com/catalog/product_info.php?products_id=47854 (verificado Sep 2015).
Specchia G, Albano F, Anelli L, [et al]. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leukemia & Lymphoma 45, 4: 689–694. 2004.
Druker B, Talpaz M, Resta D, [et al]. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine 344-a: 1031–1037, 2001.
Druker B, Sawyers C, Kantarjian H, [et al]. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England Journal of Medicine 344-b: 1038–1042, 2001.
Baccarani M, Cortes J, Pane F, [et al]. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27: 6041–6051. 2009.
Batty N, Kantarjian H, Borthakur G, [et al]. Patients with chronic myeloid leukemia with variant Philadelphia chromosome (Ph) translocations have a similar outcome as those with classic Ph when treated with imatinib or 2nd generation TKI. Blood 112: 1108. 2008.
Marzocchi G, Castagnetti F, Luatti S, [et al]. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood, 117: 6793–6800. 2011.
Baccarani M, Deininger MW, Rosti G, [et al]. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood, 122: 872-884. 2013.
Koshiyama DB, Capra ME, Paskulin G, [et al]. Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome. Ann Hematol 92:185–189. 2013.
Beligoy L, Bengio R, Bordone J, [et al]. Guías de tratamiento: Leucemia Mieloide Crónica. Sociedad Argentina de Hematología. Editora: Silvina Palmer. Tomo II: 503. Available at http://www.sah.org.ar/guias_hematolo.asp. (verificado Sep 2015).